AI-enhanced low-dose CT to screen for pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicenter observational cohort uses the PANDA artificial intelligence system to analyze low-dose CT (LDCT) images collected at participating centers. When PANDA flags an abnormality, a multidisciplinary team (MDT) reviews the finding and decides whether to recall the person for further testing, create a personalized follow-up plan, or monitor for at least one year. Primary outcomes include pancreatic cancer detection rate and positive predictive value, with secondary tracking of follow-up pathways and diagnostic yield. The protocol enrolls people aged 50 and older who complete LDCT, excluding those with prior pancreatic cancer, recent acute pancreatitis, or poor-quality scans.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 50 years and above.
2. Voluntary signing of informed consent.
3. Completion of LDCT examination.

Exclusion Criteria:

1. Previous history of pancreatic cancer.
2. Abdominal inflammation or diagnosis of acute pancreatitis within 6 months.
3. Poor image quality due to ascites, pancreatic trauma, thoracic/abdominal surgery, radiotherapy or chemotherapy.
4. Research subjects unable to complete follow-up due to physical or other reasons.

Where it's running

• Meinian Onehealth Healthcare Holdings Co., Ltd
  Shanghai, Shanghai Municipality, China Recruiting
• Ruici Medical Examination Institution
  Shanghai, Shanghai Municipality, China Recruiting
• Changhai Hospital
  Shanghai, Shanghai Municipality, China Recruiting
• Jiaxing University Affiliated Second Hospital
  Jiaxing, Zhejiang, China Recruiting
• Ningbo University Affiliated People's Hospital
  Ningbo, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Wang Bei Lei, M.D.
• Email: lilly_wang@126.com
• Phone: 13774238083

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• AI-based early detection of pancreatic cancer using routine CT scans

  This study is testing an AI system that uses regular CT scans to see if it can help find pancreatic cancer early in people who are at high risk.

  Recruiting at 3 sites Changhai Hospital · Shanghai, Shanghai Municipality and 2 other locations · NCT06638866

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.